debrisoquin has been researched along with Diathesis in 13 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It was investigated whether breast cancer patients show a similar association with respect to the oxidative status of DEB." | 5.28 | Metabolism of debrisoquine and susceptibility to breast cancer. ( Bertram, B; Huober, J; Kaufmann, M; Petru, E; Schmähl, D, 1991) |
| "Patients with bladder cancer were classified on histological criteria as having aggressive (Stage III) (34%) or nonaggressive (Stages I and II) (66%) disease." | 5.27 | Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. ( Branch, RA; Jaczq, E; Kaisary, A; McAllister, CB; Ray, WA; Smith, P; Wilkinson, GR, 1987) |
| "It was investigated whether breast cancer patients show a similar association with respect to the oxidative status of DEB." | 1.28 | Metabolism of debrisoquine and susceptibility to breast cancer. ( Bertram, B; Huober, J; Kaufmann, M; Petru, E; Schmähl, D, 1991) |
| "Patients with bladder cancer were classified on histological criteria as having aggressive (Stage III) (34%) or nonaggressive (Stages I and II) (66%) disease." | 1.27 | Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. ( Branch, RA; Jaczq, E; Kaisary, A; McAllister, CB; Ray, WA; Smith, P; Wilkinson, GR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanke, JZ | 1 |
| Vineis, P | 1 |
| Beyeler, C | 1 |
| Daly, AK | 1 |
| Armstrong, M | 1 |
| Astbury, C | 1 |
| Bird, HA | 1 |
| Idle, JR | 2 |
| Nebert, DW | 1 |
| Christensen, PM | 1 |
| Gøtzsche, PC | 1 |
| Brøsen, K | 1 |
| Nikolov, IG | 1 |
| Chernozemsky, IN | 1 |
| Huober, J | 1 |
| Bertram, B | 1 |
| Petru, E | 1 |
| Kaufmann, M | 1 |
| Schmähl, D | 1 |
| Boobis, AR | 1 |
| Davies, DS | 1 |
| May, DG | 1 |
| Black, CM | 1 |
| Olsen, NJ | 1 |
| Csuka, ME | 1 |
| Tanner, SB | 1 |
| Bellino, L | 1 |
| Porter, JA | 1 |
| Wilkinson, GR | 2 |
| Branch, RA | 2 |
| Law, MR | 1 |
| Hetzel, MR | 1 |
| Idel, JR | 1 |
| Omenn, GS | 1 |
| Vesell, ES | 1 |
| Kaisary, A | 1 |
| Smith, P | 1 |
| Jaczq, E | 1 |
| McAllister, CB | 1 |
| Ray, WA | 1 |
3 reviews available for debrisoquin and Diathesis
| Article | Year |
|---|---|
Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?
Topics: Acetylation; Animals; Arylamine N-Acetyltransferase; Bioethics; Cytochrome P-450 CYP2D6; Debrisoquin | 1997 |
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Topics: Cytochrome P-450 CYP2D6; Debrisoquin; Disease Susceptibility; Genotype; Humans; Lung Neoplasms; Odds | 1997 |
Ethnic differences in reactions to drugs and xenobiotics. Susceptibility to occupational and environmental exposures to chemicals.
Topics: Acetylation; alpha 1-Antitrypsin; Anemia, Hemolytic; Aryl Hydrocarbon Hydroxylases; Asian People; Ba | 1986 |
10 other studies available for debrisoquin and Diathesis
| Article | Year |
|---|---|
Genetic susceptibility to toxic substances and its relationship to carcinogenesis.
Topics: Acetylation; alpha 1-Antitrypsin; Aryl Hydrocarbon Hydroxylases; Carcinogens; Debrisoquin; Disease S | 1984 |
Use of biomarkers in epidemiology. The example of metabolic susceptibility to cancer.
Topics: Biomarkers; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Disease Susceptibi | 1995 |
Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Topics: Adult; Aged; Alleles; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP2D6; Cyto | 1994 |
Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Topics: Adult; Aged; Balkan Nephropathy; Bulgaria; Carcinoma, Transitional Cell; Case-Control Studies; Cytoc | 1991 |
Metabolism of debrisoquine and susceptibility to breast cancer.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Debrisoquin; Disease Susceptibility; Female; | 1991 |
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Topics: Debrisoquin; Disease Susceptibility; Gas Chromatography-Mass Spectrometry; Humans; Lung Neoplasms; O | 1990 |
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
Topics: Acetylation; Adult; Biotransformation; Dapsone; Debrisoquin; Disease Susceptibility; Female; Humans; | 1990 |
Debrisoquine metabolism and genetic predisposition to lung cancer.
Topics: Debrisoquin; Disease Susceptibility; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Age | 1989 |
Pharmacogenetic approaches to the prediction of drug response.
Topics: Debrisoquin; Disease Susceptibility; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Re | 1986 |
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Topics: Acetylation; Aged; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytoch | 1987 |